5 for 5 Hot Topics: E. David Crawford VL

DNA Next Generation Sequence in the Prevention of Infectious Complications After Transrectal Prostate Biopsy - Vladimir Mouraviev

Details
(Length of discussion ~ 6 minutes) E. David Crawford hosts a discussion with Vladimir Mouraviev on a trial regarding infection and sepsis following transrectal ultrasound-guided prostate biopsies and the use of next-generation sequencing to identify multiple organisms that pose an infection risk following these biopsies. A key finding of the trial was that based on these results, the targeted prop...

Prostate Cancer: Assorted Mortality Statistics - John Davis

Details
(Length of discussion - 6 minutes) Prostate Cancer: Assorted Mortality Statistics - John Davis E. David Crawford of the University of Colorado hosts a discussion with John Davis from MD Anderson Cancer Center on prostate cancer mortality rate in which the U.S. Services Preventive Task Force (USPSTF) claimed was 1 in 200 following radical prostatectomy (RP). Dr. Davis took a closer look at these st...

Discussion on CHAARTED, LATITUDE and STAMPEDE Trials

Details
(Length of lecture ~ 28 minutes) E. David Crawford hosts a discussion with three physicians who recently reported their findings from ASCO 2017 meeting on the CHAARTED, LATITUDE and STAMPEDE clinical trials, which will have a major impact on the treatment and survival benefits for men with prostate cancer. Elizabeth Kessler discusses the use of chemotherapy (docetaxel) in hormone sensitive metasta...

Over-treatment of Renal Tumors: The Turtle in the Room - Robert G. Uzzo

Details
(Length of discussion - 11 minutes) Kidney cancer, like all cancers, has a spectrum of risk. There are groups of patients with incidentally detected asymptomatic, small renal masses that act relatively indolent and are often over-diagnosed and over-treated in some patients. The issue is defining who they are when they should or should not be treated. Related Content: Watch: Adjuvant Therapies for...

Adjuvant Therapies for Renal Cell Carcinoma - Robert Uzzo

Details
(Length of discussion - 21 minutes) David Crawford discusses adjuvant therapy in kidney cancer with Rober Uzzo, and the fact that although there have been three decades of trials, there is still no approved therapies to treat the disease. However, Dr. Uzzo points to the S-TRAC trial as a step forward in that research space. Related Content: Watch: Over-treatment of Renal Tumors: The Turtle in the...

Immunotherapy in Bladder Cancer - Alan Bryce

Details
Immunotherapy in Bladder Cancer Biographies: E. David Crawford Alan Bryce, MD is the Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona where he utilizes whole genome sequencing of tumors to identify key driver mutations. His clinical practice centers on genitourinary malignancies (prostate, kidney, bladder, and testicular cancers) and melanoma. Dr. Bryce participates in commun...

Preliminary Data from the PROCEED Registry- Oliver Sartor

Details
Overall Survival Analysis of African Americans and Caucasian Patients Receiving Sipuleucel-T: Preliminary Data from the PROCEED Registry Read the Abstract Biographies: E. David Crawford Oliver Sartor is the only medical oncologist in Louisiana specializing in the treatment of prostate cancer patients. Dr. Sartor, the Laborde Professor of Cancer Research in the Medicine and Urology Departments of T...

Genetics in Prostate Cancer - Alan Bryce

Details
Genetics in Prostate Cancer - Germline BRCA mutations Biographies: E. David Crawford Alan Bryce, MD

PSA Versus Imaging Monitoring in mCRPC - Alan Bryce

Details
Monitoring prostate-specific antigen (PSA) vs. imaging monitoring in metastatic castration-resistant prostate cancer (mCRPC) Biographies: E. David Crawford Alan Bryce, MD Related Content: Prognostic significance of time to prostate-specific antigen (PSA)

Leonard Gomella on Bone Metastases and Mortality: Can We Be Doing More?

Details
Biography: Leonard Gomella, MD The Bernard W. Godwin, Jr. Professor of Prostate Cancer Chairman, Department of Urology Clinical Director, Jefferson Kimmel Cancer Center Network Senior Director for Clinical Affairs, Jefferson Kimmel Cancer Center